Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings


ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will present several scientific posters at the upcoming International Congress of Parkinson's Disease and Movement Disorders® on September 22-26, 2019 in Nice, France and at the annual Psych Congress on October 3-6, 2019 in San Diego, California.

Scientific poster presentations will highlight ACADIA's clinical and real-world research in central nervous system disorders with significant unmet need, including Parkinson's disease and Parkinson's disease psychosis, dementia-related psychosis, and major depressive disorder.

Scientific Presentations at the MDS Congress include:

Scientific Presentations at the Psych Congress include:

About Pimavanserin

Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in psychosis, schizophrenia, depression, and other neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. ACADIA is evaluating pimavanserin in an extensive clinical development program across multiple indications with significant unmet need including dementia-related psychosis, adjunctive major depressive disorder, and the negative symptoms of schizophrenia. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID®. NUPLAZID is not approved for dementia-related psychosis, schizophrenia or major depressive disorder.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia, major depressive disorder, and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to: the potential benefits of pimavanserin for central nervous system disorders as well as the potential results of clinical trials of pimavanserin in other indications. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA's annual report on Form 10-K for the year ended December 31, 2018 as well as ACADIA's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Important Safety Information and Indication for NUPLAZID (pimavanserin)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Indication: NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Dosage and Administration: Recommended dose: 34 mg capsule taken orally once daily, without titration.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please see the full Prescribing Information including Boxed WARNING for NUPLAZID.


These press releases may also interest you

at 18:15
Mediagrif Interactive...

at 18:06
Spring Labs is excited to announce it has successfully completed independent SOC 2 compliance audits and received its SOC 2 Type-2 Report for its Spring Protocol platform?a blockchain based platform designed to transform how information and data are...

at 18:05
Clinigence Holdings, Inc. ("Clinigence" or the "Company") , a pioneer in clinical data integration, clinical quality reporting and population health analytics, and Accountable Healthcare America, Inc. ("AHA"), a leading medical management platform...

at 18:05
NTT Research, Inc., a division of NTT (TYO:9432), today announced that its Medical and Health Informatics (MEI) Lab has entered a joint research agreement with the Technical University of Munich (TUM) to work on three-dimensionally transformable and...

at 18:04
Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced that it will be presenting new data supporting its methylation-based liver cancer...

at 18:00
Smith, a global distributor of electronic components and provider of custom supply chain services, including IT asset disposition, today announces its upcoming exhibition at DMSMS 2019. This symposium addresses diminishing manufacturing sources and...



News published on 19 september 2019 at 09:10 and distributed by: